These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21445609)

  • 1. Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy.
    Lo SM; Liu J; Chen F; Pastores GM; Knowles J; Boxer M; Aleck K; Mistry PK
    J Inherit Metab Dis; 2011 Jun; 34(3):643-50. PubMed ID: 21445609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy.
    Mistry PK; Sirrs S; Chan A; Pritzker MR; Duffy TP; Grace ME; Meeker DP; Goldman ME
    Mol Genet Metab; 2002; 77(1-2):91-8. PubMed ID: 12359135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.
    Lo SM; Stein P; Mullaly S; Bar M; Jain D; Pastores GM; Mistry PK
    Am J Hematol; 2010 May; 85(5):340-5. PubMed ID: 20425796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.
    Andrade-Campos M; Alfonso P; Irun P; Armstrong J; Calvo C; Dalmau J; Domingo MR; Barbera JL; Cano H; Fernandez-Galán MA; Franco R; Gracia I; Gracia-Antequera M; Ibañez A; Lendinez F; Madruga M; Martin-Hernández E; O'Callaghan MDM; Del Soto AP; Del Prado YR; Sancho-Val I; Sanjurjo P; Pocovi M; Giraldo P
    Orphanet J Rare Dis; 2017 May; 12(1):84. PubMed ID: 28468677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).
    Weinreb NJ; Finegold DN; Feingold E; Zeng Z; Rosenbloom BE; Shankar SP; Amato D
    Orphanet J Rare Dis; 2015 May; 10():64. PubMed ID: 25994334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease.
    Nascimbeni F; Cassinerio E; Dalla Salda A; Motta I; Bursi S; Donatiello S; Spina V; Cappellini MD; Carubbi F
    Mol Genet Metab; 2018 Sep; 125(1-2):64-72. PubMed ID: 30115580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults.
    Mistry PK; Weinreb NJ; Kaplan P; Cole JA; Gwosdow AR; Hangartner T
    Blood Cells Mol Dis; 2011 Jan; 46(1):66-72. PubMed ID: 21112800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
    Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
    Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
    Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
    Elife; 2023 May; 12():. PubMed ID: 37249220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
    Vigan M; Stirnemann J; Caillaud C; Froissart R; Boutten A; Fantin B; Belmatoug N; Mentré F
    Orphanet J Rare Dis; 2014 Jun; 9():95. PubMed ID: 24980507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy.
    Beshlawy AE; Murugesan V; Mistry PK; Eid K
    Mol Genet Metab Rep; 2019 Sep; 20():100490. PubMed ID: 31309038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients.
    Tantawy AAG; Adly AAM; Abdeen MSED; Salah NY
    Neurogenetics; 2020 Jul; 21(3):159-167. PubMed ID: 32215803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Children with type 1 Gaucher disease: Changing profiles in the 21st century.
    Elstein D; Altarescu G; Abrahamov A; Zimran A
    Blood Cells Mol Dis; 2018 Feb; 68():93-96. PubMed ID: 28185830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
    Dinur T; Bauer P; Beetz C; Kramp G; Cozma C; Iurașcu MI; Becker-Cohen M; Istaiti M; Rolfs A; Zimran A; Revel-Vilk S
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
    Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
    Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
    Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
    Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary manifestations in young Gaucher disease patients: Phenotype-genotype correlation and radiological findings.
    Gawad Tantawy AA; Moneam Adly AA; Madkour SS; Salah El-Din NY
    Pediatr Pulmonol; 2020 Feb; 55(2):441-448. PubMed ID: 31774256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive and long-term outcomes of enzyme replacement therapy followed by stem cell transplantation in children with Gaucher disease type 1 and 3.
    Anurathapan U; Tim-Aroon T; Zhang W; Sanpote W; Wongrungsri S; Khunin N; Chutipongtanate S; Chirdkiatgumchai V; Ngiwsara L; Jaovisidha S; Khongkraparn A; Pakakasama S; Svasti J; Setchell KDR; Wattanasirichaigoon D; Hongeng S
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30149. PubMed ID: 36562549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.